Clavis Pharma appoints Olav Hellebø
pharmafile | January 25, 2010 | Appointment | Research and Development, Sales and Marketing | Clavis Pharma, appointment, research and development, sales and marketing
Norwegian cancer drug development company Clavis Pharma has appointed Olav Hellebø as its new chief executive.
He joins the company on 1 February from UCB Pharma, where he was senior vice president and president of immunology operations.
In this position he built and led the global organization responsible for the successful registration and launch of Cimzia, UCB’s new antibody drug for the treatment of rheumatoid arthritis and Crohn’s disease.
From 2003 to 2004 Olav was chief operating officer of Novartis UK and prior to that held a series of senior international roles at Schering-Plough, the last as head of Schering Plough’s Oncology Biotech Division in the US.
Olav Hellebø said: “I look forward to joining Clavis Pharma at a time of great potential. The Company has achieved promising clinical data with elacytarabine in acute myeloid leukaemia and I believe this new investigational medicine can be brought successfully to market on an international basis.
”One of my key objectives at Clavis will be to build on the successes of Geir Christian Melen and his team and to further expand the clinical pipeline. I believe my commercial pharmaceutical experience will help us to establish and implement a winning international business strategy as we seek to improve outcomes for cancer patients worldwide.”
Geir Christian Melen, Clavis Pharma’s current chief executive, will continue with the company as an adviser for a transition period that is expected to last until end of June.
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
